| Full text | |
| Author(s): |
Alberca-Custodio, Ricardo Wesley
[1]
;
Faustino, Lucas D.
[2]
;
Gomes, Eliane
[1]
;
Nunes, Fernanda Peixoto Barbosa
[1]
;
de Siqueira, Mirian Krystel
[1]
;
Labrada, Alexis
[3]
;
Almeida, Rafael Ribeiro
[1]
;
Camara, Niels Olsen Saraiva
[1]
;
da Fonseca, Denise Morais
[1]
;
Russo, Momtchilo
[1]
Total Authors: 10
|
| Affiliation: | [1] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo - Brazil
[2] Harvard Med Sch, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Massachusetts Gen Hosp, Boston, MA 02115 - USA
[3] Natl Ctr Bioproducts BIOCEN, Dept Allergens, Havana - Cuba
Total Affiliations: 3
|
| Document type: | Journal article |
| Source: | FRONTIERS IN IMMUNOLOGY; v. 11, APR 23 2020. |
| Web of Science Citations: | 0 |
| Abstract | |
Changing the immune responses to allergens is the cornerstone of allergen immunotherapy. Allergen-specific immunotherapy that consists of repeated administration of increasing doses of allergen extract is potentially curative. The major inconveniences of allergen-specific immunotherapy include failure to modify immune responses, long-term treatment leading to non-compliance and the potential for developing life-threating anaphylaxis. Here we investigated the effect of a novel liposomal formulation carrying low dose of allergen combined with CpG-ODN, a synthetic TLR9 agonist, on established allergic lung inflammation. We found that challenge with allergen (OVA) encapsulated in cationic liposome induced significantly less severe cutaneous anaphylactic reaction. Notably, short-term treatment (three doses) with a liposomal formulation containing co-encapsulated allergen plus CpG-ODN, but not allergen or CpG-ODN alone, reversed an established allergic lung inflammation and provided long-term protection. This liposomal formulation was also effective against allergens derived from Blomia tropicalis mite extract. The attenuation of allergic inflammation was not associated with increased numbers of Foxp3-positive or IL-10-producing regulatory T cells or with increased levels of IFN-gamma in the lungs. Instead, the anti-allergic effect of the liposomal formulation was dependent of the innate immune signal transduction generated in CD11c-positive putative dendritic cells expressing MyD88 molecule. Therefore, we highlight the pivotal role of dendritic cells in mediating the attenuation of established allergic lung inflammation following immunotherapy with a liposomal formulation containing allergen plus CpG-ODN. (AU) | |
| FAPESP's process: | 15/25364-0 - Impact of infection-induced immunological scarring on the long-term host metabolic homeostasis |
| Grantee: | Denise Morais da Fonseca |
| Support Opportunities: | Research Grants - Young Investigators Grants |
| FAPESP's process: | 15/16728-9 - Immunotherapy of experimental asthma by agonists of toll-like receptors |
| Grantee: | Fernanda Peixoto Barbosa Nunes |
| Support Opportunities: | Scholarships in Brazil - Post-Doctoral |
| FAPESP's process: | 14/19906-2 - Transcriptional profile of t follicular helper (Tfh) cells and b cell isotype switching induced by type 1 or type 2 adjuvants |
| Grantee: | Momtchilo Russo |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 13/24694-1 - Immunotherapy of experimental asthma by agonists of toll-like receptors, infection or tolerance |
| Grantee: | Momtchilo Russo |
| Support Opportunities: | Research Projects - Thematic Grants |
| FAPESP's process: | 17/05264-7 - Cell metabolism, microbiota and immune system: new paradigms in renal diseases physiopathology |
| Grantee: | Niels Olsen Saraiva Câmara |
| Support Opportunities: | Research Projects - Thematic Grants |
| FAPESP's process: | 16/16602-8 - Immunotherapy in experimental asthma by CpG |
| Grantee: | Ricardo Wesley Alberca Custódio |
| Support Opportunities: | Scholarships in Brazil - Doctorate |